The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line (1L) trastuzumab deruxtecan (T-DXd)–based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.
 
Yelena Janjigian
Stock and Other Ownership Interests - Inspirna; OncoDaily; Veda Life Sciences
Honoraria - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; BeOne; Boehringer Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; eChinaHealth; Ed Med Resources (OncInfo); Eisai; Geneos; Genzyme; Gilead Sciences; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; i3 Health; i3 Health; IDEOlogy Health; Imedex; Imugene; Inspirna; Lilly; Lynx Health; Master Clinician Alliance; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Regeneron; Research to Practice; Seagen; Silverback Therapeutics; Suzhou Liangyihui Network Technology; Talem Health; TotalCME; WebMD; Zymeworks
Consulting or Advisory Role - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; Debbies Dream Foundation; Ed Med Resources (OncLive); Eisai; Geneos; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; Imedex; Imugene; Inspirna; Jazz Pharmaceuticals; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; OncoDaily; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Research to Practice; Seagen; Signatera; Silverback Therapeutics; WebMD; Zymeworks
Research Funding - Arcus Biosciences (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Inspirna (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Stand up to Cancer (Inst); Transcenta (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan; Merck
Other Relationship - Axis Medical Education; Clinical Care Options; Giants of Cancer Care; Research to Practice
 
Hirokazu Shoji
Consulting or Advisory Role - Astellas Pharma
Research Funding - AbbVie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Elevation Oncology (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Anna Kowalczyk
Research Funding - AstraZeneca; AstraZeneca (Inst)
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BeOne; Daiichi Sankyo; Eisai; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical; Toray Industries
Speakers' Bureau - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BeOne; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BeOne (Inst); Beringer Ingelheim (Inst); Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Jazz Pharmaceuticals (Inst); Lilly; MSD Oncology; Roche/Genentech; Sillajen
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi-Sankyo; Incyte; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi-Sankyo; Gilead Sciences; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals,; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer; Pierre Fabre; Revolution Medicines; Rottapharm Biotech; SERVIER; Takeda
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); BeOne (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Rottapharm Biotech (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Johnson & Johnson/Janssen; Merck Serono; Pierre Fabre; Takeda Science Foundation
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; ALX Oncology; Amgen; Arcus Biosciences Inc.; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CMIC Co., Ltd.; Daiichi Sankyo; eChainaHealth,Inc.; Elevation Oncology; Elevation Oncology; Gilead Sciences; GlaxoSmithKline K.K.; Guardant Health; Healios; Janssen; Leap Therapeutics; Levolution Medicines,Inc.; Moderna.Inc; MSD; Novartis; Oncolys BioPharma; Ono Pharmaceutical; Phanes Therapeutics; Sanofi; Scandion Oncology; Suzuhou Liangyihui Network Technology Co.,; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Insyte Biosciences G.K., (Inst); Medpace Japan K.K., (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PPD-SNBL (Inst); PRA Health Sciences (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)
 
Aitana Calvo Ferrándiz
Consulting or Advisory Role - AstraZeneca Spain; BMSi; Lilly; Merck
Expert Testimony - Amgen; Pierre Fabre; SERVIER
Travel, Accommodations, Expenses - Lilly; Merck; Novartis; Pharmathen
 
Hanneke Van Laarhoven
Consulting or Advisory Role - Amgen (Inst); Amphera (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Daiichi (Inst); MSD Oncology (Inst); MyeoloidTx (Inst)
Speakers' Bureau - AstraZeneca (Inst); BMS (Inst); CongressCare (Inst); Daiichy Sankyo (Inst); MedTalks (Inst); Travel Congress Management (Inst); Uitgeverij Jaap (Inst)
Research Funding - Amgen (Inst); Auristone; BMS (Inst); Incyte (Inst); Merck KGaA (Inst); ORCA Therapeutics (Inst); Servier (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Tianshu Liu
No Relationships to Disclose
 
Boguslawa Karaszewska
No Relationships to Disclose
 
Keun-Wook Lee
Honoraria - Astellas Pharma; Bayer; Celltrion; Merck KGaA; MSD Oncology; Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; BeiGene; Daiichi Sankyo; Metafines; MSD; Ono Pharmaceutical; PIN therapeutics; Takeda
Research Funding - ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avelos Therapeutics (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genome & Company (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); IDRx (Inst); IgM Biosciences (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Jazz Pharmaceuticals (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Leap Therapeutics (Inst); Medicenna (Inst); MedPacto (Inst); Merck KGaA (Inst); Metafines (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Panolos Bioscience (Inst); Pfizer (Inst); Roche (Inst); Taiho Pharmaceutical (Inst); Torl Biotherapeutics (Inst); Trishula Therapeutics (Inst); Wellmarker Bio (Inst); Yuhan (Inst)
(OPTIONAL) Uncompensated Relationships - ALX Oncology
 
Kathia Abdalla
No Relationships to Disclose
 
Eric Chen
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Incyte; Merck; Roche; Takeda
Research Funding - 1Globe Health Institute (Inst); AstraZeneca/MedImmune (Inst); BNT (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Mirati Therapeutics (Inst); Nouscom (Inst); Ono Pharmaceutical (Inst); Pfizer; Repare Therapeutics (Inst); Roche Canada (Inst)
 
Jamil Asselah
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Roche Canada
Research Funding - Celgene
 
M. Luisa Limon
No Relationships to Disclose
 
Megan Scott
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Caron Lloyd
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Eric Nwazue
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Roy Rabbie
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Jeeyun Lee
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BMS; Daichi Sankyo; Immunoncia; Samsung Bioepis (Inst); Samsung Biologics (Inst); Samsung Electronics (Inst); Trutino Biosciences
Research Funding - AstraZeneca; Merck Sharp & Dohme; Samsung Biopeis; Samsung Biopeis